Infectious complications of biological and small molecule targeted immunomodulatory therapies

JS Davis, D Ferreira, E Paige, C Gedye… - Clinical microbiology …, 2020‏ - journals.asm.org
The past 2 decades have seen a revolution in our approach to therapeutic
immunosuppression. We have moved from relying on broadly active traditional medications …

[HTML][HTML] Monoclonal antibodies in the treatment of relapsing multiple sclerosis: an overview with emphasis on pregnancy, vaccination, and risk management

N Krajnc, G Bsteh, T Berger, J Mares, HP Hartung - Neurotherapeutics, 2022‏ - Elsevier
Monoclonal antibodies have become a mainstay in the treatment of patients with relapsing
multiple sclerosis (RMS) and provide some benefit to patients with primary progressive MS …

Hepatitis B virus reactivation: what is the issue, and how should it be managed?

S Ekpanyapong, KR Reddy - Clinics in liver disease, 2020‏ - liver.theclinics.com
Hepatitis B virus (HBV) reactivation can be precipitated following the use of
immunosuppressive agents and chemotherapy and can be a serious manifestation. HBV a …

[PDF][PDF] Meta-analysis of prophylactic entecavir or lamivudine against hepatitis B virus reactivation

C Yang, B Qin, Z Yuan, L Chen, H Zhou - Annals of hepatology, 2016‏ - medigraphic.com
Introduction and aim. Introduction and aim. Studies suggest that entecavir and lamivudine
are useful as prophylactics against hepatitis B virus (HBV) reactivation in patients …

Hepatitis B virus management to prevent reactivation after chemotherapy: a review

JP Hwang, JM Vierling, AD Zelenetz, SC Lackey… - Supportive care in …, 2012‏ - Springer
Purpose Reactivation of hepatitis B virus (HBV) infection after chemotherapy can lead to
liver failure and death. Conflicting recommendations regarding HBV screening in cancer …

Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center

JP Hwang, MJ Fisch, ASF Lok, H Zhang, JM Vierling… - BMC cancer, 2013‏ - Springer
Background National organizations recommend screening for hepatitis B virus (HBV) before
chemotherapy but differ regarding which patients should be screened. We aimed to …

Hepatitis B virus DNA and RNA persist in liver after serologic recovery in persons with hepatitis C virus

T Grudda, DL Thomas, GD Kirk… - The Journal of …, 2024‏ - academic.oup.com
After recovery from a hepatitis B virus (HBV) infection, reactivation can occur with
immunosuppression; thus, it is assumed that replication competent HBV persists in the liver …

Can rituximab induce long-term disease remission in patients with intra-ocular non-infectious inflammation?

O Tomkins-Netzer, SRJ Taylor, S Lightman - Ophthalmologica, 2013‏ - karger.com
Abstract Treatment of non-infectious uveitis is based primarily on the use of systemic
corticosteroids and second-line immunosuppressive drugs. However, their extensive side …

HBV reactivation in patients receiving Bruton tyrosine kinase inhibitors (BTKIs): A systematic review and meta-analysis

A Azzam, H Khaled, BO Ashry, SM Hussein… - Current Infectious …, 2024‏ - Springer
Abstract Purpose of Review Bruton tyrosine kinase inhibitors (BTKIs) are
immunosuppressive cancer therapies approved for the treatment of various mature B-cell …

Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art

T Robak - Expert review of hematology, 2014‏ - Taylor & Francis
Anti-CD20 monoclonal antibodies (mAbs), rituximab, ofatumumab and obinutuzumab, have
a significant impact in the treatment of chronic lymphocytic leukemia (CLL), particularly in …